Search

Your search keyword '"Gopaluni, Seerapani"' showing total 15 results
Start Over Author "Gopaluni, Seerapani" Journal rheumatology
15 results on '"Gopaluni, Seerapani"'

10. 176. THE COMPOSITION OF THE HUMAN NASAL MICROBIOME IN GRANULOMATOSIS WITH POLYANGIITIS: A PILOT STUDY

Author

Kronbichler, Andreas, primary, Wagner, Josef, additional, Harrison, Ewan, additional, Pero, Marcos Martinez Del, additional, Blane, Beth, additional, Mayer, Gert, additional, Leierer, Johannes, additional, Gopaluni, Seerapani, additional, Holmes, Mark, additional, Parkhill, Julian, additional, Peacock, Sharon, additional, and Jayne, David, additional

Published
2019
Full Text
View/download PDF

11. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis

Author

Pepper, Ruth J, primary, McAdoo, Stephen P, additional, Moran, Sarah M, additional, Kelly, Dearbhla, additional, Scott, Jennifer, additional, Hamour, Sally, additional, Burns, Aine, additional, Griffith, Megan, additional, Galliford, Jack, additional, Levy, Jeremy B, additional, Cairns, Thomas D, additional, Gopaluni, Seerapani, additional, Jones, Rachel B, additional, Jayne, David, additional, Little, Mark A, additional, Pusey, Charles D, additional, and Salama, Alan D, additional

Published
2019
Full Text
View/download PDF

12. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.

Author

McClure, Mark E, Zhu, Yajing, Smith, Rona M, Gopaluni, Seerapani, Tieu, Joanna, Pope, Tasneem, Kristensen, Karl Emil, Jayne, David R W, Barrett, Jessica, and Jones, Rachel B

Subjects
INFECTION risk factors, RITUXIMAB, ANTINEUTROPHIL cytoplasmic antibodies, DISEASE relapse, RISK assessment, DECISION making, DESCRIPTIVE statistics, PREDICTION models, VASCULITIS
Abstract

Objectives Following a maintenance course of rituximab (RTX) for ANCA-associated vasculitis (AAV), relapses occur on cessation of therapy, and further dosing is considered. This study aimed to develop relapse and infection risk prediction models to help guide decision making regarding extended RTX maintenance therapy. Methods Patients with a diagnosis of AAV who received 4–8 grams of RTX as maintenance treatment between 2002 and 2018 were included. Both induction and maintenance doses were included; most patients received standard departmental protocol consisting of 2× 1000 mg 2 weeks apart, followed by 1000 mg every 6 months for 2 years. Patients who continued on repeat RTX dosing long-term were excluded. Separate risk prediction models were derived for the outcomes of relapse and infection. Results A total of 147 patients were included in this study with a median follow-up of 63 months [interquartile range (IQR): 34–93]. Relapse: At time of last RTX, the model comprised seven predictors, with a corresponding C-index of 0.54. Discrimination between individuals using this model was not possible; however, discrimination could be achieved by grouping patients into low- and high-risk groups. When the model was applied 12 months post last RTX, the ability to discriminate relapse risk between individuals improved (C-index 0.65), and once again, clear discrimination was observed between patients from low- and high-risk groups. Infection: At time of last RTX, five predictors were retained in the model. The C-index was 0.64 allowing discrimination between low and high risk of infection groups. At 12 months post RTX, the C-index for the model was 0.63. Again, clear separation of patients from two risk groups was observed. Conclusion While our models had insufficient power to discriminate risk between individual patients they were able to assign patients into risk groups for both relapse and infection. The ability to identify risk groups may help in decisions regarding the potential benefit of ongoing RTX treatment. However, we caution the use of these prediction models until prospective multi-centre validation studies have been performed. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

13. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis

Author

Pepper, Ruth J, primary, McAdoo, Stephen P, additional, Moran, Sarah M, additional, Kelly, Dearbhla, additional, Scott, Jennifer, additional, Hamour, Sally, additional, Burns, Aine, additional, Griffith, Megan, additional, Galliford, Jack, additional, Levy, Jeremy B, additional, Cairns, Thomas D, additional, Gopaluni, Seerapani, additional, Jones, Rachel B, additional, Jayne, David, additional, Little, Mark A, additional, Pusey, Charles D, additional, and Salama, Alan D, additional

Published
2018
Full Text
View/download PDF

14. novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis.

Author

Pepper, Ruth J, McAdoo, Stephen P, Moran, Sarah M, Kelly, Dearbhla, Scott, Jennifer, Hamour, Sally, Burns, Aine, Griffith, Megan, Galliford, Jack, Levy, Jeremy B, Cairns, Thomas D, Gopaluni, Seerapani, Jones, Rachel B, Jayne, David, Little, Mark A, Pusey, Charles D, and Salama, Alan D

Subjects
THERAPEUTIC use of glucocorticoids, VASCULITIS
Abstract

A correction to the article "A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis" is presented.

Published
2019
Full Text
View/download PDF

15. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis

Author

Alan D. Salama, Rachel B Jones, Stephen P. McAdoo, Jennifer Scott, Thomas D. Cairns, Dearbhla M Kelly, Charles D. Pusey, Sally Hamour, Megan Griffith, Jack Galliford, Seerapani Gopaluni, David Jayne, Ruth J. Pepper, Jeremy Levy, Sarah M Moran, Mark A. Little, Aine Burns, Gopaluni, Seerapani [0000-0002-1584-6186], Jayne, David [0000-0002-1712-0637], and Apollo - University of Cambridge Repository

Subjects
medicine.medical_specialty, Cyclophosphamide, medicine.medical_treatment, 030232 urology & nephrology, SYSTEMIC VASCULITIS, Gastroenterology, vasculitis, 1117 Public Health and Health Services, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, medicine, Pharmacology (medical), RITUXIMAB, DAILY ORAL CYCLOPHOSPHAMIDE, Adverse effect, Dialysis, 030203 arthritis & rheumatology, GRANULOMATOSIS, therapy, Science & Technology, glucocorticoids, ANCA, business.industry, INDUCTION, 1103 Clinical Sciences, REMISSION, EFFICACY, medicine.disease, RANDOMIZED-TRIAL, RHEUMATOID-ARTHRITIS, Arthritis & Rheumatology, Regimen, 1107 Immunology, adverse effects, Rituximab, business, Vasculitis, Life Sciences & Biomedicine, medicine.drug, Systemic vasculitis
Abstract

OBJECTIVES: Glucocorticoids (GCs) are a mainstay of treatment for patients with ANCA-associated vasculitis (AAV) but are associated with significant adverse effects. Effective remission induction in severe AAV using extremely limited GC exposure has not been attempted. We tested an early rapid GC withdrawal induction regimen for patients with severe AAV. METHODS: Patients with active MPO- or PR3-ANCA vasculitis or ANCA-negative pauci-immune glomerulonephritis were included. Induction treatment consisted of two doses of rituximab, 3 months of low-dose CYC and a short course of oral GC (for between 1 and 2 weeks). Clinical, biochemical and immunological outcomes as well as adverse events were recorded. RESULTS: A total of 49 patients were included, with at least 12 months of follow-up in 46. All patients achieved remission, with decreases observed in creatinine, proteinuria, CRP, ANCA level and BVAS. Three patients requiring dialysis at presentation became dialysis independent. Two patients required the introduction of maintenance GC for treatment of vasculitis. Overall outcomes were comparable to those of two matched cohorts (n = 172) from previous European Vasculitis Society (EUVAS) trials, but with lower total exposure to CYC and GCs (P < 0.001) and reduced rates of severe infections (P = 0.02) compared with the RITUXVAS (rituximab versus cyclophosphamide in AAV) trial. We found no new cases of diabetes in the first year compared with historic rates of 8.2% from the EUVAS trials (P = 0.04). CONCLUSION: Early GC withdrawal in severe AAV is as effective for remission induction as the standard of care and is associated with reduced GC-related adverse events.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results